[HTML][HTML] Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis
JY Chen, YN Cheng, L Han, F Wei, WW Yu… - Cancer biology & …, 2015 - ncbi.nlm.nih.gov
Objective A meta-analysis was performed to augment the insufficient data on the impact of
mutative EGFR downstream phosphatidylinositol-3-kinase (PI3K) and mitogen-activated …
mutative EGFR downstream phosphatidylinositol-3-kinase (PI3K) and mitogen-activated …
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR …
V Ludovini, F Bianconi, L Pistola, V Minotti… - Cancer chemotherapy …, 2012 - Springer
Background We present a comprehensive analysis of KRAS, PIK3CA, MET, and non-
sensitizing EGFR mutations in advanced non-small cell lung cancer (NSCLC) patients …
sensitizing EGFR mutations in advanced non-small cell lung cancer (NSCLC) patients …
Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis
M Ying, X Zhu, K Chen, Z Sha, L Chen - Journal of cancer research and …, 2015 - Springer
Purpose Regarding the controversial investigations characterizing the role of KRAS status
for predicting patients' response to epidermal growth factor receptor tyrosine kinase …
for predicting patients' response to epidermal growth factor receptor tyrosine kinase …
[HTML][HTML] Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
X Qiu, Y Wang, F Liu, L Peng, C Fang… - American journal of …, 2021 - ncbi.nlm.nih.gov
In non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor
(EGFR) mutation, the prognostic impact of a concurrent Phosphoinositide-3-kinase catalytic …
(EGFR) mutation, the prognostic impact of a concurrent Phosphoinositide-3-kinase catalytic …
[HTML][HTML] Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven …
J Eng, KM Woo, CS Sima, A Plodkowski… - Journal of Thoracic …, 2015 - Elsevier
Introduction In patients with epidermal growth factor receptor (EGFR)-mutant or KRAS-
mutant lung adenocarcinomas, the prognostic impact of a concurrent PIK3CA mutation …
mutant lung adenocarcinomas, the prognostic impact of a concurrent PIK3CA mutation …
KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies
Epidemiologic studies have evaluated the association between KRAS mutations and
resistance to the treatment of epidermal growth factor receptor (EGFR) tyrosine-kinase …
resistance to the treatment of epidermal growth factor receptor (EGFR) tyrosine-kinase …
[HTML][HTML] Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine …
V Ludovini, F Bianconi, L Pistola, R Chiari… - Journal of thoracic …, 2011 - Elsevier
Background: Specific mutations of the epidermal growth factor receptor (EGFR) gene are
predictive for favorable response to tyrosine kinase inhibitors (TKIs) and are associated with …
predictive for favorable response to tyrosine kinase inhibitors (TKIs) and are associated with …
Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy
O Fiala, M Pesek, J Finek, L Benesova… - Anticancer …, 2013 - ar.iiarjournals.org
Background: Epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene
(KRAS) and phosphatidylinositide-3-kinase catalytic subunit-alpha (PIK3CA) mutations are …
(KRAS) and phosphatidylinositide-3-kinase catalytic subunit-alpha (PIK3CA) mutations are …
[HTML][HTML] Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers
CY Liu, HF Lin, WY Lai, YY Lin, TW Lin… - Journal of the …, 2022 - journals.lww.com
Lung carcinoma (LC) is the third most common cancer diagnosis and accounted for the most
cancer-related mortality worldwide in 2018. Based on the type of cells from which it …
cancer-related mortality worldwide in 2018. Based on the type of cells from which it …
KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non–small cell lung cancer: clues for its potential use in …
AD Campos-Parra, C Zuloaga… - American journal of …, 2015 - journals.lww.com
Objetive: In patients with non–small cell lung cancer (NSCLC), knowledge of the epidermal
growth factor receptor (EGFR) mutation status is fundamental for selecting the treatment …
growth factor receptor (EGFR) mutation status is fundamental for selecting the treatment …
Related searches
- egfr tkis meta analysis
- egfr tkis lung cancer
- meta analysis lung cancer
- egfr tkis predictive value
- meta analysis predictive value
- egfr tki treatment efficacy
- lung cancers pik3ca mutations
- egfr tki cell nsclc
- egfr tki pik3ca mutations
- egfr tkis patient selection
- meta analysis kras mutation
- routine predictor lung cancer
- cell nsclc pik3ca mutations
- treatment efficacy pik3ca mutations
- poor prognosis pik3ca mutations
- egfr mutations combined analysis